An Open, Multicenter Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House

Trial Profile

An Open, Multicenter Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs House dust mite allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Adverse reactions
  • Sponsors Bial; Roxall Medizin GmbH
  • Most Recent Events

    • 19 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 28 Apr 2017 Planned End Date changed from 1 Jul 2017 to 1 Dec 2017.
    • 28 Apr 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top